Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671148 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
A Phase 3 study of Psoriatic Arthritis (PsA), sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
- 20
- Study locations
NCT03671148: Active Phase 3 study of Psoriatic Arthritis (PsA), sponsored by AbbVie.
NCT03671148 is a Phase 3 study of Psoriatic Arthritis (PsA) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 444 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03671148, a Phase 3 study of Psoriatic Arthritis (PsA), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Primary Outcome
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Risankizumab
Study Locations (20)
Florida
- Arthritis & Rheumatic Disease Specialties /ID# 212582 - Aventura
- SIMED Health, LLC /ID# 207457 - Gainesville
- Sweet Hope Research Specialty Inc /ID# 168163 - Hialeah
- Rheum Assoc of Central FL /ID# 201629 - Orlando
- HMD Research LLC /ID# 208428 - Orlando
- Millennium Research /ID# 201627 - Ormond Beach
- Arthritis Center, Inc. /ID# 208116 - Palm Harbor
- IRIS Research and Development, LLC /ID# 166351 - Plantation
- BayCare Medical Group /ID# 201630 - St. Petersburg
- West Broward Rheumatology Associates /ID# 201234 - Tamarac
- University of South Florida /ID# 208467 - Tampa
California
- St. Jude Heritage /ID# 166842 - Fullerton
- Newport Huntington Medica /ID# 207423 - Huntington Beach
- Arthritis & Osteo Medical Ctr /ID# 166541 - La Palma
- East Bay Rheumatology Medical /ID# 166845 - San Leandro
- Inland Rheum Clin Trials Inc. /ID# 166621 - Upland
Connecticut
- New England Research Associates, LLC /ID# 166525 - Bridgeport
- Yale University /ID# 166330 - New Haven
Alabama
- Pinnacle Research Group /ID# 167953 - Anniston
Colorado
- Denver Arthritis Clinic /ID# 166442 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What the registry record for NCT03671148 still lists
NCT03671148 is an interventional study that assigns participants to a tested intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Psoriatic Arthritis (PsA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03671148 names 20 study sites across 5 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03671148 about?
NCT03671148 is a clinical study titled "A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)". The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
What is the current status of trial NCT03671148?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2019-03-07. Estimated completion is 2026-06.
What conditions does trial NCT03671148 study?
This clinical trial studies the following conditions: Psoriatic Arthritis (PsA).
What interventions are being tested in trial NCT03671148?
The interventions under investigation include: Placebo (BIOLOGICAL), Risankizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03671148?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03671148 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis (PsA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03671148's enrollment target sits among peer trials
444 865th of 2000 higher than 1,135 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI